Abstract. MicroRNAs (miRs) serve important roles in cancer genesis and progression. The expression of miR-1908 has been reported in a number of types of cancer; however, the clinical significance of miR-1908 in human ovarian cancer (OC) remains unclear. A total of 491 patients with OC from The Cancer Genome Atlas project cohort were selected and divided into two groups according to the median expression level of miR-1908. Univariate and multivariate analyses, using the Kaplan-Meier method and Cox regression, were performed to identify the characteristics that predict OC prognosis. Bioinformatics tools were used to identify potential targets of miR-1908. It was identified that the low expression of miR-1908 is associated with a poor prognosis for OC (P<0.05). The potential target genes of miR-1908 included podocan-like 1, JunB AP-1 transcription factor subunit, homeobox B8, SET binding factor 1 and sirtuin 2; high expression of these five genes additionally predicted a poor prognosis. These results suggest that miR-1908 may be a suitable target for the development of novel approaches in OC diagnosis and therapy in the future.
Introduction
Ovarian cancer (OC) is the most lethal of all gynecological tumors; there are >204,000 newly diagnosed patients and 125,000 mortalities annually, worldwide (1) . The 5-year survival rate for OC is <50%; the main reason is the high frequency of OC recurrence subsequent to therapy (2) . In order to improve estimates of the prognosis of OC and to develop novel treatments, novel OC biomarkers are required.
MicroRNAs (miRNAs/miRs) are non-protein coding genes that consist of <30 nucleotides; they serve important roles in a large number of cell behaviors, typically by downregulating target protein-coding genes. The dysregulation of miRNA expression is associated with a range of diseases, including the development of tumors (3) . miR-1908 is regarded as an oncogene in numerous types of tumor (4) . The miRNA functions as an oncogene through suppressing phosphatase and tensin homolog (PTEN), a tumor suppressor; this function promotes the proliferation and invasiveness of tumor cells in glioblastoma and osteosarcoma (5) . miR-1908 expression is also regarded as a potential biomarker for breast cancer (6) . Overall, a number of studies have identified that miR-1908 may be useful as a prognostic biomarker (7) (8) (9) . However, it is necessary to clarify the functional and clinical importance of each miRNA in specific types of cancer, so that it is able to offer an improved proposal for therapeutics in the future. As the 5-year survival rate of OC is poor, biomarkers to predict the prognosis of patients with OC are required to improve the diagnosis of this disease. Therefore, the present study used data on patients with OC from The Cancer Genome Atlas (TCGA) cohort to identify whether miR-1908 was significantly associated with the prognosis of OC.
Patients and methods

Patients and samples.
Patients with OC were selected from the TCGA cohort (https://portal.gdc.cancer.gov/). Patients included in the present study were those with fully characterized tumors, complete overall and disease-free survival time information, and complete miRNAseq and mRNAseq data. The clinical characteristics that were considered in the present study included age, tumor grade, clinical stage (American joint committee on cancer) (10), tumor size, lymphatic invasion, anatomical neoplasm subdivision and ethnicity. Python version 2.7.5 (https://www. python.org/download/releases/2.7.5/) and R version 3.2.0 (https://cran.r-project.org/bin/windows/base/old/3.2.0/) were used to screen the data of the TCGA OC cohort according to their patient IDs.
Identification of potential targets for miR-1908.
The bioinformatics tools Targetscan (http://www.targetscan.org/) and microRNA.org (http://www.microrna.org/) were used to predict target genes for miR-1908. The top 100 highest-scoring genes were initially selected from each database to give 200 potential targets. Duplicates were then removed from the list to give a list of 131 potential target genes.
Statistical analysis. SPSS version 21 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis and the construction of statistical plots. The values are presented as the mean ± the standard error of mean, and the values between the two groups were compared with independent t-test. Overall survival time was defined as the time from the date of diagnosis to the date of cancer-associated patient mortality or last follow-up. Disease-free survival time was defined as the time from the date of diagnosis to the date of first recurrence or cancer-associated patient mortality. Patients without further events or recorded mortality were regarded as censored at the time of the last follow-up. Patients were separated into two groups depending on the expression of miR-1908, with the cut-off being the median expression level. Survival curves were produced using the Kaplan-Meier (KM) method, and log-rank tests were used to assess the survival differences between the high expression group and the low expression group. The adjusted hazard ratio (HR) was calculated using the Cox proportional hazards model. Univariate and multivariate Cox proportional HR of miRNA expression and overall survival were analyzed. A two-sided P<0.05 was considered to indicate a statistically significant difference.
Results
Clinical characteristics of the OC cohort. miR-1908 expression and clinical data of patients with OC from the TCGA cohort were sorted to identify 491 cases where clinical and miRNA data were available. The basic clinical features of the 491 patients with OC are summarized in Table I . The mean age at the time of the initial pathological diagnosis was 59.5 years (standard deviation, ±11.5) and patients ranged from 30 to 87 years old. The majority of the patients from the cohort (70.7%) were at clinical stage IIIC and 84% had a tumor grade of G4, indicating that OC may be difficult to identity and diagnose in the early stages. The median follow-up time for the cohort was 30.3 months; during this time, 270 patients (55.0%) succumbed to the disease.
High expression level of miR-1908 is an independent positive prognostic factor for patients with OC.
By analyzing the association between the expression level of miR-1908 and the overall survival time of patients with OC, it was identified that the high expression level of miR-1908 may be a protective factor in the cancer. To investigate whether the expression status of miR-1908 has potential as an OC prognostic marker, univariate and multivariate analyses using the KM method and Cox regression were performed. The OC cases were divided into two groups with the cut-off being the median level of miR-1908 expression.
From the univariate Cox proportional hazards model analysis, it was determined that age, tumor size, clinical stage and miR-1908 expression level were significantly associated with the overall survival time of patients with OC in the TCGA cohort (P<0.05; Table II) . A multivariate Cox proportional hazards model analysis was performed to identify independent factors for the prediction of prognosis in OC; the result indicated that miR-1908 expression level was an independent predictor of the overall survival time of patients with OC (HR, 0.673; 95% CI, 0.520-0.872; P<0.05; Table II ). The KM plot for miR-1908 is presented in Fig. 1 . The result indicates that the low expression of miR-1908 predicts a poor prognosis in terms of overall ( Fig. 1A; P<0 .05) and disease-free ( Fig. 1B; P<0 .05) survival time. Multivariate logistic regression analyses of characteristics that may affect the expression of miR-1908 were performed. It was identified that miR-1908 expression was significantly associated with age (HR, 2.518; 95% CI, 1.305-4.860; P=0.006; Table III) . In order to further analyze the age-associated expression difference of miR-1908, the cohort was divided into two groups according to the median age (≥60 vs. <60 years). The mean expression of miR-1908 was significantly higher in the ≥60 years group than that in the <60 years group (P<0.001; Fig. 1C ).
Prediction of miR-1908 target genes with bioinformatics analysis.
Following the survival analysis of 131 potential target genes, 10 genes were determined to be associated with prognosis in OC (Table IV; Fig. 2A) . The low expression of the potential target genes podocan-like 1 (PODNL1), junB AP-1 transcription factor subunit (JUNB), homeobox B8 (HOXB8), SET binding factor 1 (SBF1) and sirtuin 2 (SIRT2) was associated with a significantly increased survival time (Fig. 2B-F) . As the high expression of miR-1908 is associated with an improved prognosis and it has the ability to bind to the 3'-untranslated region (UTR) of these 5 genes, as illustrated in Fig. 2G , we hypothesize that these 5 genes are potential targets for miR-1908 that determine its effect on the prognosis of patients with OC.
Discussion
miRNA dysregulation is a common characteristic of numerous types of cancer, and miRNAs serve key functions in tumor genesis and progression, including cell proliferation, differentiation, migration and invasion (11) . OC is associated with a poor prognosis and a high mortality rate due to its high likelihood of recurrence. Therefore, more prognostic markers are required to improved estimates of patient survival time and construct personalized plans for therapy. In the present study, miR-1908 was identified as a biomarker for predicting the survival time of patients with OC. Patients with OC from the TCGA cohort were selected, and their clinical, RNAseq and mRNAseq data were analyzed. It was identified that the high expression of miR-1908 may be a protective factor for OC, as high expression was associated with improved survival time for patients with the cancer.
In glioblastoma, miR-1908 functions as an oncogene by repressing the PTEN pathway (11) . Overexpression of miR-1908 significantly promoted tumor growth, as demonstrated in vitro and in vivo. Additionally, the expression levels of miR-1908 Table III . Multivariate logistic regression analysis of the association between patient characteristics and miR-1908 expression. were significantly increased in patient tumor samples and its high expression was associated with a reduction in survival time (11) . Another study identified that the low expression of miR-1908 predicted a poor prognosis in glioma (12) . In addition, miR-1908 has also been associated with the prognosis of chordoma, hepatoma and melanoma (13) (14) (15) (16) . miR-1908 has different functions in different cancer types, as it may target different genes.
-------------------------------------------------------------------------------------------------------------------------------------------------
According to the present study, SIRT2, PODNL1, SBF1, JUNB and HOXB8 are likely to be the targets of miR-1908 in OC. These genes are associated with the overall survival time of OC patients, as low expression of these genes predicts an improved prognosis, and miR-1908 is able to regulate them by binding their 3'UTRs. SIRT2 is a NAD-dependent deacetylase that is involved in a number of cellular processes, including cell proliferation, death, senescence and stress responses (17, 18) . PONDL1 is a transcription factor; however, its function remains unclear (19) . SBF1 encodes a member of the protein-tyrosine phosphatase family; this protein contains a guanine nucleotide exchange factor domain, necessary for its role in cell growth and differentiation (16) . JUNB promotes tumor metastasis and progress; silencing of JUNB resulted in reduced cell growth and colony formation associated with decreased activator protein-1 activity, and G1/S or G2/M cell cycle arrest (20) . HOXB8 is a member of the ANTP homeobox family and encodes a nuclear protein with a homeobox DNA-binding domain. The high expression of cytoplasmic HOXB8 was associated with a significantly reduced progression-free survival time, whereas high nuclear HOXB8 expression was associated with significantly shorter overall survival time in an analysis limited to patients with post-chemotherapy effusions (21) . miR-1908 may target these genes to suppress the progress of OC and increase the survival time of patients with OC.
In conclusion, the present study demonstrated that the expression of miR-1908 is significantly associated with the overall survival time of patients with OC. The high expression of miR-1908 predicts a better prognosis by conferring a longer survival time. The low expression of miR-1908 may be a valuable biomarker to identify patients with OC with a poor prognosis. Potential target genes of miR-1908 were identified; these targets are likely to have functions in tumor genesis and progression. These data may support novel approaches for the diagnosis and therapy of patients with OC in the future.
